Baxter once again plans to add to its IV solutions business – this time through the acquisition Baxa Corporation for $380 million in cash. Baxa is a privately held company that has developed pharmacy devices and software that improves the safety of oral and IV dose preparation and delivery.
Baxter makes $380M grab for Baxa to boost IV and oral delivery
Baxter once again plans to add to its IV solutions business – this time through the acquisition Baxa Corporation for $380 million in cash. Baxa is a privately held company that has developed pharmacy devices and software that improves the safety of oral and IV dose preparation and delivery.
More from Alimentary/Metabolic
• By
Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.
• By
Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.
• By
Two Phase III trials testing tegoprazan read out positively, but the potassium-competitive acid blocker will compete with Phathom’s Voquezna (vonoprazan).
• By
The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.
More from Therapeutic Category
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.
• By
As the PDUFA date for the UK major’s IL-5 inhibitor draws close.